Key European Patent Granted for Immunic's Vidofludimus Calcium, Extending Exclusivity to 2038
IMUX has more than doubled off its 52-week low of $0.506.
Summary
Immunic announced the European Patent Office has granted a key patent protecting relevant dosing regimens for its lead asset, vidofludimus calcium (IMU-838). This patent is expected to provide market exclusivity in Europe into 2038, with potential for extension to 2043, significantly strengthening the intellectual property portfolio for the late-stage drug candidate. While a similar patent was granted in the US in 2023, this European grant is a material positive development, reducing future generic competition risk and enhancing the long-term commercial value of vidofludimus calcium, which is currently in Phase 3 trials for multiple sclerosis. Investors will continue to monitor clinical trial progress and further IP developments.
At the time of this announcement, IMUX was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.1M. The 52-week trading range was $0.51 to $1.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: EQS.